300791 Stock Overview
Operates as a contract manufacturer for dietary supplement industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Sirio Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.47 |
| 52 Week High | CN¥35.48 |
| 52 Week Low | CN¥19.32 |
| Beta | 0.88 |
| 1 Month Change | 4.90% |
| 3 Month Change | 17.89% |
| 1 Year Change | 11.51% |
| 3 Year Change | -9.29% |
| 5 Year Change | 38.56% |
| Change since IPO | 5.67% |
Recent News & Updates
When Should You Buy Sirio Pharma Co., Ltd. (SZSE:300791)?
Dec 13
Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?
Oct 14The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More
Sep 30Recent updates
When Should You Buy Sirio Pharma Co., Ltd. (SZSE:300791)?
Dec 13Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?
Oct 14The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More
Sep 30Is Sirio Pharma (SZSE:300791) Using Too Much Debt?
Sep 23Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares
Aug 01Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around
Jun 30Is Sirio Pharma (SZSE:300791) A Risky Investment?
Jun 12An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued
Apr 24Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly
Mar 06Shareholder Returns
| 300791 | CN Personal Products | CN Market | |
|---|---|---|---|
| 7D | -4.8% | -2.5% | -1.2% |
| 1Y | 11.5% | -4.7% | 11.8% |
Return vs Industry: 300791 exceeded the CN Personal Products industry which returned -4.7% over the past year.
Return vs Market: 300791 matched the CN Market which returned 11.8% over the past year.
Price Volatility
| 300791 volatility | |
|---|---|
| 300791 Average Weekly Movement | 8.6% |
| Personal Products Industry Average Movement | 7.9% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300791 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300791's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,610 | Peiqing Li | www.siriopharma.com |
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging.
Sirio Pharma Co., Ltd. Fundamentals Summary
| 300791 fundamental statistics | |
|---|---|
| Market cap | CN¥6.67b |
| Earnings (TTM) | CN¥335.69m |
| Revenue (TTM) | CN¥4.13b |
19.9x
P/E Ratio1.6x
P/S RatioIs 300791 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300791 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.13b |
| Cost of Revenue | CN¥2.85b |
| Gross Profit | CN¥1.27b |
| Other Expenses | CN¥938.91m |
| Earnings | CN¥335.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 30.88% |
| Net Profit Margin | 8.13% |
| Debt/Equity Ratio | 46.1% |
How did 300791 perform over the long term?
See historical performance and comparisonDividends
3.0%
Current Dividend Yield59%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sirio Pharma Co., Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Huang | Chasing Securities |
| Wenbo Chen | China International Capital Corporation Limited |
| Wendan Wang | China International Capital Corporation Limited |